Recipharm welcomes Tobias Hägglöv as Chief Financial Officer

Report this content

Recipharm AB (publ) announces that Tobias Hägglöv takes office as new Chief Financial Officer, effective today. Tobias will be a member of Recipharm Group Management team and reports to Thomas Eldered, Chief Executive Officer of Recipharm.

Tobias Hägglöv has comprehensive experience in finance and management positions. He joins Recipharm from a position as the CFO at LEAX. Prior to that, Tobias Hägglöv served at Electrolux, SAS and Accenture. Tobias holds a degree in Finance and Business Administration from the University of Stockholm, and a M.Sc. from Royal Institute of Technology, Stockholm, Sweden.

Contact information
Thomas Eldered, CEO, telephone: +46 8 602 52 10, ir@recipharm.com

This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 3 October 2018, at 10:00 am CET.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00

www.recipharm.com

Tags: